Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Prednisolone, Rituximab, Vincristine in patients with Follicular Lymphoma.
This statement is based on a regulatory approval from the Health Canada:
RITUXAN (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.